Teva announced the availability of Alyq (tadalafil) tablets, the generic version of Adcirca (tadalafil; Eli Lilly), for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Alyq, a selective inhibitor of cyclic guanosine monophosphate (cGMP)–specific phosphodiesterase type 5 (PDE5), works by increasing the concentrations of cGMP in the pulmonary vascular smooth muscle resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. Studies establishing effectiveness included predominately patients with NYHA Functional Class II to III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).
Alyq should not be used with concomitant organic nitrates or guanylate cyclase (GC) stimulators (eg, riociguat), and in patients with a known serious hypersensitivity to tadalafil.
Alyq is supplied as 20mg tablets in 60-count bottles.